{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:07:05Z","timestamp":1792318025401,"version":"4.4.0"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T00:00:00Z","timestamp":1361318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Studies assessing the impact of epilepsy and its medication on the risk of road traffic crashes have shown inconsistent results. The aim in this study was to assess this risk using French databases. Data from three French national databases were extracted and matched: the national health care insurance database, police reports, and the national police database of injurious crashes. Only antiepileptics prescribed predominantly in epilepsy were studied (phenobarbital, phenytoin, ethosuximide, valproic acid, vigabatrin, tiagabin, levitiracetam, zonisamide, and lacosamide). A case\u2013control analysis comparing responsible and non\u2010responsible drivers and a case\u2013crossover analysis were performed. Drivers (72\u2009685) involved in an injurious crash in France between July 2005 and May 2008, were included. Drivers exposed to prescribed antiepileptic medicines (n\u2009=\u2009251) had an increased risk of being responsible for a crash (OR 1.74 [1.29\u20132.34]). The association was also significant for the most severe epileptic patients (n\u2009=\u200999; OR\u2009=\u20092.20 [1.31\u20133.69]). Case\u2013crossover analysis found no association between crash risk and treatment prescription. Patients with prescription of antiepileptic drugs should be cautioned about their potential risk of road traffic crash. This risk is however more likely to be related to seizures than to the effect of antiepileptic medicines.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jcph.10","type":"journal-article","created":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T21:27:18Z","timestamp":1361395638000},"page":"339-344","source":"Crossref","is-referenced-by-count":21,"title":["Prescription of Antiepileptics and the Risk of Road Traffic Crash"],"prefix":"10.1002","volume":"53","author":[{"given":"Ludivine","family":"Orriols","sequence":"first","affiliation":[{"name":"Centre INSERM U897\u2010Epidemiologie\u2010Biostatistique Univ. Bordeaux, ISPED Bordeaux France"},{"name":"INSERM, Equipe Pr\u00e9vention et prise en charge des traumatismes ISPED, Centre INSERM U897\u2010Epidemiologie\u2010Biostatistique Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Foubert\u2010Samier","sequence":"additional","affiliation":[{"name":"Centre INSERM U897\u2010Epidemiologie\u2010Biostatistique Univ. Bordeaux, ISPED Bordeaux France"},{"name":"INSERM, Equipe Epid\u00e9miologie et neuropsychologie du vieillissement c\u00e9r\u00e9bral ISPED, Centre INSERM U897\u2010Epidemiologie\u2010Biostatistique Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Gadegbeku","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lyon Lyon France"},{"name":"IFSTTAR, UMR T 9405 UMRESTTE Bron France"},{"name":"Universit\u00e9 Lyon 1, UMRESTTE Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Delorme","sequence":"additional","affiliation":[{"name":"P\u00f4le information des professionnels et du public, Direction de la communication et de l'information Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM) Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Tricotel","sequence":"additional","affiliation":[{"name":"P\u00f4le \u00e9pid\u00e9miologie des produits de sant\u00e9, Direction de la surveillance Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM) Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Philip","sequence":"additional","affiliation":[{"name":"USR CNRS SANPSY 3413 Universit\u00e9 Bordeaux Segalen Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Moore","sequence":"additional","affiliation":[{"name":"INSERM U657, CIC\u2010P0005, D\u00e9partement de Pharmacologie Universit\u00e9 Bordeaux Segalen Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Lagarde","sequence":"additional","affiliation":[{"name":"Centre INSERM U897\u2010Epidemiologie\u2010Biostatistique Univ. Bordeaux, ISPED Bordeaux France"},{"name":"INSERM, Equipe Pr\u00e9vention et prise en charge des traumatismes ISPED, Centre INSERM U897\u2010Epidemiologie\u2010Biostatistique Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the CESIR Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101033240105"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.3.435"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.60.6.621"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31820e7b3b"},{"key":"e_1_2_8_6_1","first-page":"28","article-title":"Newer anticonvulsants in the treatment of bipolar disorder","volume":"65","author":"Yatham LN.","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e318059361a"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03600-X"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.44.s4.3.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060010-00003"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1993.tb02102.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1324"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000366"},{"key":"e_1_2_8_14_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9.Epilepsies graves. Guide\u2010Affections de Longue Dur\u00e9e;2007."},{"key":"e_1_2_8_15_1","unstructured":"CastotA.Delorme B and the working group \u201cmedicinal products and driving.\u201d Medicinal products and driving: how to assess the risk? P2T Congress Marseille; 2009. Abstract no. 481."},{"key":"e_1_2_8_16_1","unstructured":"Arr\u00eat\u00e9 du 8 ao\u00fbt 2008 pris pour l'application de l'article R. 5121\u2013139 du code de la sant\u00e9 publique et relatif \u00e0 l'apposition d'un pictogramme sur le conditionnement ext\u00e9rieur de certains m\u00e9dicaments et produits."},{"key":"e_1_2_8_17_1","unstructured":"Afssaps.Medicinal Products Driving. 2009. Available online atwww.afssaps.fr\/var\/afssaps_site\/storage\/original\/application\/e5f2e48d5344bcfef6ca865ac63e7c3d.pdfAccessed August 29 2011."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0001-4575(94)90094-9"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38648.617986.1F"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115853"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.10.1613"},{"issue":"2","key":"e_1_2_8_22_1","first-page":"295","article-title":"Epileptic drivers\u2014A study of 1\u2009089 patients","volume":"16","author":"Beaussart M","year":"1997","journal-title":"Med Law."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2004.05.004"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1975.tb04760.x"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.10","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T03:00:37Z","timestamp":1698634837000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,20]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1002\/jcph.10"],"URL":"https:\/\/doi.org\/10.1002\/jcph.10","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,20]]}}}